



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/50, 33/68, A61K 31/70, 37/02	A1	(11) International Publication Number: WO 94/12876	(43) International Publication Date: 9 June 1994 (09.06.94)
---	----	---	--

(21) International Application Number: PCT/GB93/02430

(22) International Filing Date: 25 November 1993 (25.11.93)

(30) Priority Data:
9224956.4 28 November 1992 (28.11.92) GB

(71) Applicant (for all designated States except US): EURO/DPC LIMITED [GB/GB]; Glyn Rhonwy, Llanberis, Caernarfon, Gwynedd LL55 4EL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HELM, Birgit, Anna [DE/GB]; 17 Oak Brook Court, Riverdale Park, Sheffield S10 3HR (GB). WILSON, Anne, Penelope, Margaret [GB/GB]; 6 Stable Mews, Mill Lane, Beaumaris, Anglesey, Gwynedd LL58 8BL (GB). MOREIRA-MACHADO, Denise [BR/GB]; 453 Springvale Road, Sheffield S10 1LQ (GB). PULLAR, Christine, Elaine [GB/GB]; 92 Heavygate Road, Walkley, Sheffield S10 1PF (GB). CAMP, Andrew [GB/GB]; 21 Grosvenor Square, Sheffield S2 4NS (GB).

(74) Agent: WILLIAM, Jones; The Crescent, 54 Blossom Street, York, North Yorkshire YO2 2AP (GB).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: ALLERGEN/INFLAMMATORY TESTING AND DIAGNOSIS

(57) Abstract

The invention relates to the use of a secretor variant cell-line expressing the alpha moiety of human IgE binding protein to determine the allergic status of a given individual. Moreover, the cell-line is also used to provide an assay system for determining the allergenicity of substances and for subsequently providing therapeutic compositions which render said substances ineffective. In addition, the invention also relates to the use of said cell-line to determine the IgE independent irritancy of substances and compositions effective for attenuating the effects of said substances.